Shire Receives “Reduce” Rating from AlphaValue (SHP)
Shire (LON:SHP)‘s stock had its “reduce” rating reaffirmed by investment analysts at AlphaValue in a note issued to investors on Thursday, AnalystRatingsNetwork reports. They currently have a GBX 2,338 ($37.45) price objective on the stock. AlphaValue’s price target would indicate a potential downside of 5.61% from the stock’s previous close.
Shares of Shire (LON:SHP) traded down 0.16% during mid-day trading on Thursday, hitting GBX 2473.00. 574,102 shares of the company’s stock traded hands. Shire has a 1-year low of GBX 1682.00 and a 1-year high of GBX 2602.00. The stock has a 50-day moving average of GBX 2432.08 and a 200-day moving average of GBX 2167.18. The company’s market cap is £13.592 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Shire (LON:SHP) in a research note to investors on Wednesday. They now have a GBX 2,750 ($44.05) price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Shire (LON:SHP) in a research note to investors on Tuesday. They now have a GBX 2,660 ($42.61) price target on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Shire (LON:SHP) in a research note to investors on Thursday, September 19th. They now have a GBX 38 ($0.61) price target on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of GBX 2,060.02 ($33.00).
Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.